- Home
- KPRX vs DTST Comparison
KPRX vs DTST Comparison
Compare KPRX & DTST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KPRX | DTST |
|---|---|---|
| Founded | 1998 | 2001 |
| Country | United States | United States |
| Employees | N/A | 55 |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0M | 8.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | KPRX | DTST |
|---|---|---|
| Price | $2.54 | $3.98 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 617.6K | 20.4K |
| Earning Date | 05-08-2026 | 04-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $25.39 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $2.31 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.76 | $3.25 |
| 52 Week High | $4.18 | $5.44 |
Technical Indicators
Market Signals| Indicator | KPRX | DTST |
|---|---|---|
| Relative Strength Index (RSI) | 62.75 | 46.59 |
| Support Level | $1.90 | $3.30 |
| Resistance Level | $2.94 | $4.32 |
| Average True Range (ATR) | 0.21 | 0.25 |
| MACD | 0.05 | 0.04 |
| Stochastic Oscillator | 65.79 | 29.27 |
Price Performance
Historical ComparisonAbout KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About DTST Data Storage Corporation
Data Storage Corporation engages in providing cybersecurity, compliance and cloud computing solutions. The company's segment includes Nexxis Inc; CloudFirst Europe Ltd and CloudFirst Technologies Corporation and Corporate. It generates maximum revenue from the CloudFirst Technologies Corporation segment. The company's solutions include infrastructure, disaster recovery, email archival, compliance, electronic vaulting, virtualized recovery, telecom recovery services, and continuous data protection.